Repository logo
 
Publication

The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2)

2015-06-04Journal article Restricted access
Simple item page
dc.contributor.authorValenciano, Marta
dc.contributor.authorKissling, Esther
dc.contributor.authorReuss, Annicka
dc.contributor.authorJiménez-Jorge, Silvia
dc.contributor.authorHorváth, Judit K.
dc.contributor.authorDonnell, Joan M.O.
dc.contributor.authorPitigoi, Daniela
dc.contributor.authorMachado, Ausenda
dc.contributor.authorPozo, Francisco
dc.contributor.authorI-MOVE Multicentre Case Control Study Team
dc.date.accessioned2016-02-25T14:52:16Z
dc.date.available2019-01-01T01:30:10Z
dc.date.issued2015-06-04
dc.description.abstractBACKGROUND: In the first five I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) influenza seasons vaccine effectiveness (VE) results were relatively homogenous among participating study sites. In 2013-2014, we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in six European Union (EU) countries to measure 2013-2014 influenza VE against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. Influenza A(H3N2) and A(H1N1)pdm09 viruses co-circulated during the season. METHODS: Practitioners systematically selected ILI patients to swab within eight days of symptom onset. We compared cases (ILI positive to influenza A(H3N2) or A(H1N1)pdm09) to influenza negative patients. We calculated VE for the two influenza A subtypes and adjusted for potential confounders. We calculated heterogeneity between sites using the I(2) index and Cochrane's Q test. If the I(2) was <50%, we estimated pooled VE as (1 minus the OR)×100 using a one-stage model with study site as a fixed effect. If the I(2) was >49% we used a two-stage random effects model. RESULTS: We included in the A(H1N1)pdm09 analysis 531 cases and 1712 controls and in the A(H3N2) analysis 623 cases and 1920 controls. For A(H1N1)pdm09, the Q test (p=0.695) and the I(2) index (0%) suggested no heterogeneity of adjusted VE between study sites. Using a one-stage model, the overall pooled adjusted VE against influenza A(H1N1)pdm2009 was 47.5% (95% CI: 16.4-67.0). For A(H3N2), the I(2) was 51.5% (p=0.067). Using a two-stage model for the pooled analysis, the adjusted VE against A(H3N2) was 29.7 (95% CI: -34.4-63.2). CONCLUSIONS: The results suggest a moderate 2013-2014 influenza VE against A(H1N1)pdm09 and a low VE against A(H3N2). The A(H3N2) estimates were heterogeneous among study sites. Larger sample sizes by study site are needed to prevent statistical heterogeneity, decrease variability and allow for two-stage pooled VE for all subgroup analyses.pt_PT
dc.description.sponsorshipEuropean Center for Disease Prevention and Controlpt_PT
dc.identifier.citationVaccine. 2015 Jun 4;33(24):2813-22. doi: 10.1016/j.vaccine.2015.04.012. Epub 2015 Apr 28.pt_PT
dc.identifier.doi10.1016/j.vaccine.2015.04.012pt_PT
dc.identifier.issn0264-410X
dc.identifier.urihttp://hdl.handle.net/10400.18/3501
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relationInitiative for the MObility and deVElopment of researchers’careers
dc.subjectCuidados de Saúdept_PT
dc.subjectVacina da Gripept_PT
dc.subjectEfetividade da Vacina Antigripalpt_PT
dc.subjectGripept_PT
dc.subjectInfluenzapt_PT
dc.subjectVaccine Effectivenesspt_PT
dc.subjectEuropept_PT
dc.subjectI-MOVEpt_PT
dc.subjectInfluenza Vaccinept_PT
dc.subjectInfluenza Vaccine Effectivenesspt_PT
dc.subjectMulticentre Studypt_PT
dc.subjectTest-negative designpt_PT
dc.titleThe European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2)pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleInitiative for the MObility and deVElopment of researchers’careers
oaire.awardURIinfo:eu-repo/grantAgreement/EC/FP7/267232/EU
oaire.citation.endPage2822pt_PT
oaire.citation.startPage2813pt_PT
oaire.citation.titleVaccinept_PT
oaire.citation.volume33(24)pt_PT
oaire.fundingStreamFP7
project.funder.identifierhttp://doi.org/10.13039/501100008530
project.funder.nameEuropean Commission
rcaap.rightsembargoedAccesspt_PT
rcaap.typearticlept_PT
relation.isProjectOfPublicationeb7f5a38-f4e2-4b0d-831e-b5dc916b55fe
relation.isProjectOfPublication.latestForDiscoveryeb7f5a38-f4e2-4b0d-831e-b5dc916b55fe

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
The European I-MOVE Multicentre 2013–2014 Case-Control Study.pdf
Size:
473.22 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DEP - Artigos em revistas internacionais